Bicycle Therapeutics has been granted a patent for peptide ligands that target human plasma Kallikrein. The patent claims a method of treating various ophthalmic disorders, including age-related macular degeneration and diabetic retinopathy, by administering a peptide ligand with specific amino acid sequences. The ligand forms covalent bonds with reactive groups and has a molecular scaffold. The patent provides a detailed description of the specific amino acid sequences and structural features of the ligand. GlobalData’s report on Bicycle Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Bicycle Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Bicycle Therapeutics's grant share as of September 2023 was 16%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for a method of treating retinal disorders
A recently granted patent (Publication Number: US11753444B2) describes a method for suppressing or treating impaired retinal vessel permeability or various ophthalmic disorders. The method involves administering a peptide ligand specific for human plasma Kallikrein to a patient in need. The peptide ligand consists of a polypeptide with three reactive groups separated by two loop sequences, attached to a molecular scaffold. The loops of the peptide ligand contain five amino acids and have a specific motif. The peptide bond between two of the amino acids is replaced by ?CH2NH.
The patent claims cover the use of the peptide ligand for treating a wide range of ophthalmic disorders, including age-related macular degeneration (ARMD), exudative macular degeneration, macular edema, diabetic retinopathy, and various retinal vein occlusions. The method involves administering a therapeutically effective amount of the peptide ligand to the patient.
The patent also describes the use of specific amino acids and molecular scaffolds in the peptide ligand. For example, the first loop of the polypeptide can contain azetidine carboxylic acid, and the fifth amino acid in the loop can be N-methyl arginine, homoarginine, or guanidylphenylalanine. The molecular scaffold can be tris(bromomethyl)benzene or its derivatives, such as 1,3,5-tris(bromomethyl)-2,4,6-trimethylbenzene or 1,3,5-tris(bromomethyl)-2,4,6-triethylbenzene.
Furthermore, the patent claims cover the attachment of the peptide ligand to an antibody or a fragment thereof. The antibody fragment can include various constant region domains, such as an antibody light chain constant region (CL), an antibody CH1 heavy chain domain, an antibody CH2 heavy chain domain, or an antibody CH3 heavy chain domain. The hinge region or Fc region of an IgG molecule can also be part of the antibody or fragment.
Overall, this granted patent describes a method for suppressing or treating impaired retinal vessel permeability and various ophthalmic disorders using a specific peptide ligand. The method involves administering the peptide ligand, which is attached to an antibody or a fragment thereof, to the patient. The patent provides specific details about the amino acid composition, molecular scaffold, and antibody attachment, offering potential therapeutic options for patients with these ophthalmic conditions.
To know more about GlobalData’s detailed insights on Bicycle Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
